BR112022014272A2 - Fator de crescimento derivado de mieloide para uso no tratamento ou prevenção de fibrose, hipertrofia ou insuficiência cardíaca - Google Patents
Fator de crescimento derivado de mieloide para uso no tratamento ou prevenção de fibrose, hipertrofia ou insuficiência cardíacaInfo
- Publication number
- BR112022014272A2 BR112022014272A2 BR112022014272A BR112022014272A BR112022014272A2 BR 112022014272 A2 BR112022014272 A2 BR 112022014272A2 BR 112022014272 A BR112022014272 A BR 112022014272A BR 112022014272 A BR112022014272 A BR 112022014272A BR 112022014272 A2 BR112022014272 A2 BR 112022014272A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- hypertrophy
- fibrosis
- heart failure
- myeloid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20153008 | 2020-01-21 | ||
| PCT/EP2021/051079 WO2021148411A1 (en) | 2020-01-21 | 2021-01-19 | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014272A2 true BR112022014272A2 (pt) | 2022-09-20 |
Family
ID=69187588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014272A BR112022014272A2 (pt) | 2020-01-21 | 2021-01-19 | Fator de crescimento derivado de mieloide para uso no tratamento ou prevenção de fibrose, hipertrofia ou insuficiência cardíaca |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230059560A1 (https=) |
| EP (1) | EP4093750A1 (https=) |
| JP (1) | JP7777532B2 (https=) |
| KR (1) | KR20220131262A (https=) |
| CN (1) | CN115698048A (https=) |
| AU (1) | AU2021211874A1 (https=) |
| BR (1) | BR112022014272A2 (https=) |
| CA (2) | CA3164500A1 (https=) |
| MX (1) | MX2022008727A (https=) |
| PH (1) | PH12022551792A1 (https=) |
| TW (1) | TW202142254A (https=) |
| WO (1) | WO2021148411A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022066729A1 (en) * | 2020-09-22 | 2022-03-31 | Wisconsin Alumni Research Foundation | Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor |
| US20250325704A1 (en) | 2020-12-23 | 2025-10-23 | Boehringer Ingelheim International Gmbh | Viral capsid proteins with specificity to heart tissue cells |
| CN115820829B (zh) * | 2022-03-22 | 2026-04-17 | 中国人民解放军军事科学院军事医学研究院 | Mydgf在防治记忆损伤及其相关疾病中的应用 |
| JP2025518285A (ja) | 2022-06-03 | 2025-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 骨髄由来増殖因子の組換え発現 |
| JP2025530232A (ja) | 2022-09-08 | 2025-09-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心原性ショックの処置に用いる骨髄由来成長因子 |
| EP4480490A1 (en) * | 2023-06-23 | 2024-12-25 | Medizinische Hochschule Hannover | Brick1 for use in treating myocardial diseases |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| TW202539726A (zh) | 2023-12-06 | 2025-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 包含骨髓衍生性生長因子之新穎調配物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| AU717542B2 (en) | 1996-06-11 | 2000-03-30 | Merck & Co., Inc. | Synthetic hepatitis C genes |
| WO1998011217A2 (en) * | 1996-09-13 | 1998-03-19 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS |
| JP2001506484A (ja) | 1996-09-13 | 2001-05-22 | 財団法人相模中央化学研究所 | 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ |
| CA2503390A1 (en) | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004069173A2 (en) | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| US20080004232A1 (en) | 2006-05-09 | 2008-01-03 | John Wilkins | Characterization of c19orf10, a Novel Synovial Protein |
| EP2130547A1 (en) | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| DK2945642T3 (da) * | 2013-01-17 | 2024-05-27 | Medizinische Hochschule Hannover | Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme |
| JP7405772B2 (ja) * | 2018-05-09 | 2023-12-26 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物 |
| WO2020176732A1 (en) * | 2019-02-27 | 2020-09-03 | Icahn School Of Medicine At Mount Sinai | TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY |
-
2021
- 2021-01-19 US US17/759,056 patent/US20230059560A1/en active Pending
- 2021-01-19 EP EP21701283.0A patent/EP4093750A1/en active Pending
- 2021-01-19 CA CA3164500A patent/CA3164500A1/en active Pending
- 2021-01-19 TW TW110102010A patent/TW202142254A/zh unknown
- 2021-01-19 BR BR112022014272A patent/BR112022014272A2/pt unknown
- 2021-01-19 CN CN202180022864.1A patent/CN115698048A/zh active Pending
- 2021-01-19 JP JP2022544144A patent/JP7777532B2/ja active Active
- 2021-01-19 AU AU2021211874A patent/AU2021211874A1/en active Pending
- 2021-01-19 WO PCT/EP2021/051079 patent/WO2021148411A1/en not_active Ceased
- 2021-01-19 MX MX2022008727A patent/MX2022008727A/es unknown
- 2021-01-19 PH PH1/2022/551792A patent/PH12022551792A1/en unknown
- 2021-01-19 KR KR1020227027546A patent/KR20220131262A/ko active Pending
- 2021-01-19 CA CA3223879A patent/CA3223879A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022551792A1 (en) | 2023-09-18 |
| EP4093750A1 (en) | 2022-11-30 |
| MX2022008727A (es) | 2022-10-07 |
| CA3164500A1 (en) | 2021-07-29 |
| AU2021211874A1 (en) | 2022-08-25 |
| WO2021148411A1 (en) | 2021-07-29 |
| JP7777532B2 (ja) | 2025-11-28 |
| KR20220131262A (ko) | 2022-09-27 |
| TW202142254A (zh) | 2021-11-16 |
| JP2023511358A (ja) | 2023-03-17 |
| CN115698048A (zh) | 2023-02-03 |
| US20230059560A1 (en) | 2023-02-23 |
| CA3223879A1 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014272A2 (pt) | Fator de crescimento derivado de mieloide para uso no tratamento ou prevenção de fibrose, hipertrofia ou insuficiência cardíaca | |
| McCain et al. | Matrix elasticity regulates the optimal cardiac myocyte shape for contractility | |
| Gregorich et al. | Top-down targeted proteomics reveals decrease in myosin regulatory light-chain phosphorylation that contributes to sarcopenic muscle dysfunction | |
| BR112015022971A2 (pt) | métodos de fabricação para controlar o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes | |
| BR112017008108A2 (pt) | incorporação de aminoácidos não naturais em proteínas | |
| MX2021014952A (es) | Molecula de union especifica para cd73 y uso de la molecula de union. | |
| NO20083266L (no) | Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser | |
| BR112012019881A2 (pt) | proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23 | |
| BR112019001108A2 (pt) | usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc | |
| BR112023005674A2 (pt) | Construtos anti-cd93 e usos dos mesmos | |
| BR112019011860A2 (pt) | proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune | |
| BRPI0713000A8 (pt) | Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples | |
| BR112022004047A2 (pt) | Proteínas de ligação multiespecíficas para o tratamento de câncer | |
| BR112018003753A2 (pt) | bifidobacterium longum | |
| BR112022008075A2 (pt) | Métodos de seqüênciamento de proteínas de célula única e de ácido nucleico | |
| BR112017025929A2 (pt) | genes pesticidas e métodos de uso | |
| Yuen et al. | Nonmuscle myosin is regulated during smooth muscle contraction | |
| BR112022012327A2 (pt) | Anticorpos ou fragmentos dos mesmos, ácido nucleico, vetor e célula hospedeira | |
| CL2025002422A1 (es) | Métodos y composiciones para la administración de sistemas de vector dual otoferlin. | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| BR112015026707A2 (pt) | Proteína ppr, e, complexo | |
| BR112021020727A2 (pt) | Materiais e métodos para produção de proteína | |
| BR112013018744A2 (pt) | método para produzir um polipetídeo ou uma proteína recombinante | |
| BR112022019571A2 (pt) | Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula | |
| MX2016006277A (es) | Secuencia de endolisina kz144 modificada. |